https://scholars.lib.ntu.edu.tw/handle/123456789/540140
標題: | Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure | 作者: | YI-CHING TUNG YEN-HSUAN NI HONG-SHIEE LAI Hsieh D.-Y. MEI-HWEI CHANG |
公開日期: | 2006 | 出版社: | Scientific Communications International Ltd | 卷: | 105 | 期: | 5 | 起(迄)頁: | 399-403 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: Home parenteral nutrition (HPN) is being increasingly used to treat children with intestinal failure. This study evaluated the long-term growth, outcome and complications in Taiwanese pediatric patients with intestinal failure who were treated with HPN. Methods: This retrospective study included 27 consecutive pediatric patients with intestinal failure who received long-term HPN between 1987 and 2002. These patients were categorized into two groups according to whether they had short bowel syndrome or a bowel motility disorder. Growth, prognosis and complications, including cholestasis, hypoglycemia, hyperglycemia and infections were compared between the two groups. Results: The median age of starting HPN was significantly younger in patients with short bowel syndrome (5 months) than in patients with motility disorders (1.9 years). The median duration of HPN treatment in the overall group was 13.5 months (range, 2.1-113.1 months); weight and height increased 1.7 ± 2.3 and 1.0 ± 1.6 in z score, respectively. The most common complications were cholestatic liver disease (52%), hypoglycemia (15%) and hyperglycemia (33%). All patients maintained stable serum glucose levels at follow-up. Cholestatic liver disease developed after 2.3 ± 2.0 months of total HPN in 13 patients, which subsided after 9.7 ± 6.9 months in 11 patients, while two patients died. The mean incidence of central venous infection was 3.0 ± 3.3 per 1000 HPN days. The most common pathogens were Staphylococcus spp. (50%) and Candida spp. (30.6%). Conclusion: HPN treatment can successfully provide a bridge to enteral nutrition in pediatric patients with intestinal failure. The metabolic disturbances and cholestasis are usually transient, but infection control is important throughout the period of HPN treatment. ?2006 Elsevier & Formosan Medical Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645908777&doi=10.1016%2fS0929-6646%2809%2960136-4&partnerID=40&md5=9b614e69d5463e45d36cb5c903340602 https://scholars.lib.ntu.edu.tw/handle/123456789/540140 |
ISSN: | 0929-6646 | DOI: | 10.1016/S0929-6646(09)60136-4 | SDG/關鍵字: | adolescent; article; body height; body weight; Candida; child; child growth; cholestasis; clinical article; controlled study; enteric feeding; enteropathy; female; home care; human; hyperglycemia; hypoglycemia; incidence; infant; infection; infection control; intestinal dysmotility; intrahepatic cholestasis; long term care; male; metabolic disorder; outcome assessment; parenteral nutrition; patient coding; prognosis; retrospective study; scoring system; short bowel syndrome; Staphylococcus; Taiwan; treatment duration |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。